Howard Fingert

Safety, Pharmacokinetic, and Pharmacodynamic Phase I Dose-Escalation Trial of PF-00562271, an Inhibitor of Focal Adhesion Kinase, in Advanced Solid Tumors

Jeffrey R. Infante, D. Ross Camidge, Linda Mileshkin et al. · Journal of Clinical Oncology · 2012 · 238 citations

Medicine, Oncology, Pharmacology +16

Phase II Study of Alisertib, a Selective Aurora A Kinase Inhibitor, in Relapsed and Refractory Aggressive B- and T-Cell Non-Hodgkin Lymphomas

Jonathan W. Friedberg, Daruka Mahadevan, Erin Cebula et al. · Journal of Clinical Oncology · 2013 · 209 citations · Full text

Medicine, Hematology, Pharmacology +17

In vitro evidence that myocardial ischemia resulting from 5-fluorouracil chemotherapy is due to protein kinase C-mediated vasoconstriction of vascular smooth muscle.

Morris Mosseri, Howard Fingert, Lyuba Varticovski et al. · PubMed · 1993 · 198 citations

Medicine, Cardiology, Pharmacology +17

Phase I Study of Aurora A Kinase Inhibitor MLN8237 in Advanced Solid Tumors: Safety, Pharmacokinetics, Pharmacodynamics, and Bioavailability of Two Oral Formulations

Elizabeth Claire Dees, Roger B. Cohen, Margaret von Mehren et al. · Clinical Cancer Research · 2012 · 156 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +17

Phase I Pharmacokinetic/Pharmacodynamic Study of MLN8237, an Investigational, Oral, Selective Aurora A Kinase Inhibitor, in Patients with Advanced Solid Tumors

Andrés Cervantes, Elena Élez, Desamparados Roda et al. · Clinical Cancer Research · 2012 · 150 citations

Medicine, Oncology, Pharmacology +17